Win payer acceptance for expensive new treatments

New drugs can be very expensive, costing a single patient tens of thousands of dollars a month. While many of these medicines prolong lives, it may be difficult using conventional trial data alone to demonstrate that they provide real value relative to their cost.

Using RWE, pharmaceutical companies can work with payers to determine exactly who benefits from these expensive therapies. When the evidence shows that a specific group of patients will receive outsized benefits from a particular medicine, then insurers are willing to cover it.